Actively Recruiting

Phase Not Applicable
Age: 19Years - 85Years
All Genders
NCT06990477

Effect of EIT-guided PEEP in ARDS Patients With Higher Recruitability

Led by Southeast University, China · Updated on 2026-02-02

264

Participants Needed

3

Research Sites

159 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury. Positive end-expiratory pressure (PEEP), as one of main component of MV, has been widely used in the clinical practice. However, the PEEP selection is still a difficult problem for moderate to severe ARDS patients. EIT, an imaging tool evaluating the regional ventilation distribution at the bedside, can achieve the individual PEEP selection for all mechanically ventilated patients. Our previous study found that moderate to severe ARDS patients with higher recruitability could benefit from EIT-guided PEEP. This article compared the effect of PEEP titrated guided by EIT with fraction of inspired oxygen (FiO2)-PEEP table on the clinical outcomes in patients with higher recruitability.

CONDITIONS

Official Title

Effect of EIT-guided PEEP in ARDS Patients With Higher Recruitability

Who Can Participate

Age: 19Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Moderate-to-severe ARDS defined by the Berlin definition (PaO2:FiO2 ratio ≤ 200 mmHg with PEEP ≥ 5 cmH2O)
  • RI ratio greater than 0.5 measured within the previous 24 hours
  • Diagnosis of ARDS within less than 72 hours
Not Eligible

You will not qualify if you...

  • Expected mechanical ventilation duration less than 48 hours
  • Severe chronic respiratory diseases needing long-term oxygen therapy or noninvasive mechanical ventilation
  • Undrained pneumothorax or subcutaneous emphysema
  • Receiving extracorporeal membrane oxygenation (ECMO) before enrollment
  • Contraindications to EIT use (e.g., pacemaker, implantable cardioverter defibrillator, implantable pumps)
  • Severe neuromuscular disease
  • Hemodynamic instability
  • Contraindications to hypercapnia such as intracranial hypertension or acute coronary syndrome
  • Severe organ dysfunction with low expected survival (7 days) or palliative care
  • Solid organ or blood cancers with expected survival less than 30 days
  • Participation in other clinical trials within 30 days
  • Pregnancy
  • Refusal to sign informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Department of Critical Care Medicine, Zhongshan Hospital of Fudan University

Shanghai, China Mainland, China, 200000

Not Yet Recruiting

2

Department of Critical Care Medicine, Renji Hospital

Shanghai, China Mainland, China, 20000

Not Yet Recruiting

3

Zhongda Hospital, School of Medicine, Southeast University

Nanjing, Jiangsu, China, 210009

Actively Recruiting

Loading map...

Research Team

Y

yuan xue yan, MD, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here